secwatch.observer — SEC 8-K summary
======================================

Issuer:     PAVmed Inc. (PAVM)
CIK:        0001624326
Form:       8-K
Filed at:   2026-05-15T12:05:34+00:00
Accession:  0001493152-26-023352
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PAVmed Q1 GAAP net loss $7.0M; Lucid Diagnostics revenue $1.3M, 3,177 tests
---------------------------------------------------------------------------

- GAAP net loss $7.0M ($4.42 diluted EPS); non-GAAP adjusted loss $1.9M ($1.17 per share).
- Cash and equivalents $6.5M at Mar 31, up from $1.5M at Dec 31, 2025.
- Lucid Diagnostics Q1 EsoGuard revenue $1.3M, 3,177 tests processed; raised $17M in public offering, proforma cash $45M.
- Veris Health advancing implantable physiological monitor towards FDA 510(k) submission.
- PAVmed relaunched medical device portfolio including PortIO and Duke-licensed endoscopic imaging.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/0001493152-26-023352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-023352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer